Literature DB >> 12833893

[Cutaneous graft-versus-host disease].

S Karrer1.   

Abstract

Although stem cell transplantation is a life-saving measure and the treatment of choice for many patients with various hematologic malignancies, a high incidence of complications and a transplantation associated mortality of about 30% are to be expected.Graft-versus-Host Disease (GvHD) is the major cause of morbidity and mortality after stem cell transplantation. GvHD can arise at various time points. Acute GvHD occurs during the first 100 days after transplantation in up to 50% of graft recipients, while chronic GvHD develops in about 30-50% usually within 100-500 days following allogeneic stem cell transplantation. It can involve the skin, liver, gastrointestinal tract, and less frequently the lungs, eyes and neuromuscular system. Early diagnosis of GvHD can be difficult, as drug reactions, viral infections and cutaneous reactions to radiation therapy may have clinical and histological similarities. In this review, the various cutaneous manifestations of GvHD, the histopathologic features, prophylaxis and therapy of acute and chronic GvHD are discussed in light of the recent literature.

Entities:  

Mesh:

Year:  2003        PMID: 12833893     DOI: 10.1007/s00105-003-0528-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  37 in total

Review 1.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

2.  Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.

Authors:  J Grimm; W Zeller; A R Zander
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

3.  Acute follicular graft-vs-host disease.

Authors:  B A Lycka; V N Kaye
Journal:  Arch Dermatol       Date:  1988-09

4.  Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.

Authors:  J Cavet; P G Middleton; M Segall; H Noreen; S M Davies; A M Dickinson
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

Review 5.  Unrelated donor hematopoietic transplantation.

Authors:  M de Lima; R Champlin
Journal:  Rev Clin Exp Hematol       Date:  2001-06

Review 6.  Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.

Authors:  David A Jacobsohn; Georgia B Vogelsang
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Late appearance of acute graft-vs-host disease after suspending or tapering immunosuppressive drugs.

Authors:  R Valks; J Fernández-Herrera; B Bartolomé; J Fraga; E Daudén; A Garcia-Diéz
Journal:  Arch Dermatol       Date:  2001-01

8.  Cytokine expression in human cutaneous chronic graft-versus-host disease.

Authors:  L A Ochs; B R Blazar; J Roy; E B Rest; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  1996-06       Impact factor: 5.483

9.  Parafollicular hair bulge in human GVHD: a stem cell-rich primary target.

Authors:  G E Sale; M Beauchamp
Journal:  Bone Marrow Transplant       Date:  1993-03       Impact factor: 5.483

View more
  1 in total

1.  [Graft-versus-Host Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and classification of GvHD].

Authors:  R Travnik; M Beckers; D Wolff; E Holler; M Landthaler; S Karrer
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.